Relationship between neuropathy, hypertension and red blood cell Na/K ATPase in patients with insulin-dependent diabetes mellitus

Diabetes and Metabolism

Volumn 25, Issue 1, 1999, Pages 35-42

  Jannot, M F ^b   Raccah, D ^b   Dufayet De La Tour, D ^b   Coste, T ^b   Gouvernet, J ^b   Vague, Philippe ^a  

^a TIMONE HOSPITAL   (France)

^b NONE

Author keywords

Angiotensin converting enzyme inhibitor; Diabetic neuropathy; Hypertension; Microvascular hypothesis; Na K ATPase activity; Risk factors

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE DURATION; ERYTHROCYTE METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; RISK FACTOR; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; ERYTHROCYTES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; NA(+)-K(+)-EXCHANGING ATPASE; RISK FACTORS; TRIGLYCERIDES;

EID: 0032898593     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Raccah D, Gallice P, Pouget J, Vague P. Hypothesis low Na/K ATPase activities of the red cell membrane, a potentiel marker of the predisposition to diabetic neuropathy. Diabetes Metab, 1992, 18, 236-241.
2. Raccah D, Fabreguettes C, Azoulay J.P, Vague P. Erythrocytes N + -K + -ATPase activity, metabolic control and neuropathy in IDDM patients. Diabetes Care, 1996, 19, 564-568.
3. Vague P, Dufayet D, Coste T, Moriscot C, Jannot M.F, Raccah D. Association of diabetic neuropathy with NaK ATPase gene polymorphism. Diabetologia, 1997, 40, 506-511.
4. Raccah D, Jannot MK, Issautier D, Vague P. Effect of experimental diabetes on Na/KATPase activity in red blood cells, peripheral nerve and kidney. Diabetes Metab, 1994, 20, 271-274.
5. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Eng J Med, 1487, 316, 594-605.
6. Finotti P, Palatini P. Reduction of erythrocyte Na + K + ATPase activity in type I (insulin-dependent) diabetic subjects and its activation by homologous plasma. Diabetes, 1987, 36, 991-995.
7. Tanyalcin T, Kutay F, Soydan I, Erlacin S. Erythrocyte Na/K ATPase activity does not predict therapeutic response to calcium antagonists in essential hypertension Clin Chem, 1994, 40, 1532-1536.
8. Forrest KYZ, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy. Diabetes, 1997, 46, 665-670.
9. Bodansky HJ, Cudworth AG, Drury PL, Kohner EM. Risk factors associated with severe proliferative retinopathy in insulin-dependent diabetes mellitus. Diabetes Care, 1982, 5, 97-100.
10. Parving HH, Andersen AR, Smidt UM, Svensen PAA. Early agressive anti-hypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet, 1983, 1, 1175-1178.
11. Maser RE, Steenkiste A, Dorman J, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study. Diabetes, 1989, 38, 1456-1461.
12. Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF Risk factors for distal symmetric neuropathy in NIDDM : the San Luis Valley Diabetes Study. Diabetes Care, 1994, 17, 1172-1177.
13. Harris M, Cowie C, Eastman R. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care, 1993, 16, 1446-1452.
14. Beutler E, Kuhl E, Sacks P. Sodium potassium ATPase activity is influenced by ethnic origin and not by obesity. N Engl J Med, 1983, 309, 756-760.
15. The Diabetes Control and Complications Trial Research Group. Factors in the development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetic control and complications trials. Diabetes, 1988, 37, 471-481.
16. Beutler E, West C, Blume KG. The removal of leucocytes and platelets from whole blood. J Lab Clin Med, 1976, 88, 328-333.
17. Hosmer, Lemeshow : Goodness of fit tests for the multiple logistic regression model. Commun. Statist, Part, A theor Meth, A9 10, 1043-1069.
18. Orchard T, Dorman J, Maser R, et al. Factors associated with avoidance of severe complications after 25 years of IDDM. Pittsburgh epidemiology of diabetes complications study I. Diabetes Care, 1990, 13, 741-747.
19. Ziegler D, Gries F, Spüler M, Lessmann F. the DiaCAN Multicenter Study Group. The epidemiology of diabetic neuropathy. Diabetic Med, 1993, 10[suppl. 2] :82S-86S.
20. Flynn MD, Tooke JE. Diabetic neuropathy and microcirculation. Diabetic Med, 1995, 12, 298-301.
21. Blaustein MP. Sodium ions and blood pressure regulation and hypertension : a hypothesis. Ant J Physiol, 1977, 232, C165-C173.
22. Haddy FJ, Pamnani MB. Evidence for a circulating endogenous Na/K pump inhibitor in low renin hypertension. Federation Proceedings, 1985, 44, 2789-2794.
23. Lechi C, Corrodini P, Polignana R, Boradonna G, Delva P, Lechi A. Measurement by bioluminescence technique of crythrocyte membrane Na + K + ATPase activity in hypertensive patients, Clin Chim Acta, 1987, 163, 329-337.
24. Stojadinovic N, Petronijevic M, Pavicevic M, Mrsulja B, Kostic M. Alteration of erythrocyte membrane Na/K ATPase in children with borderline or essential hypertension. Cell Biochemistry & Function, 1996, 14, 79-87.
25. Herrera VLM, Ruiz-Opazo N. Alteration of alphal Na/K ATPase 86 Rb + influx by a single amino acid substitution. Science, 1990, 249, 1023-1026.
26. Schull MM, Hassendrin D, Loggie J, et al. Discordant segregation of Na/K Adenosine triphosphatase alleles and essential hypertension. J Hypertension, 1992, 10, 1005-1010.
27. Worthington M, Whendt M, Opie L. Sodium transport in hypertension : assessment of membrane associated defects in South African black and white hypertensives. Journal of Human Hypertension, 1993, 7, 291-297.
28. Graves SW. The sodium pump in hypertension. Current Opinion in Nephrology and Hypertension, 1994, 3, 107-111.
29. Lunbaek K. Long-term diabetes. The clinical picture in diabetes mellitus of 15-25 years duration with a follow-up of a regional series of cases. Copenhagen : Ejnar Munksgard, 1953
30. Malik RA, Tesfaye S, Thompson SD, Veves A, Boulton AJM, Ward ID. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia, 1993, 36 454-459.
31. Malik RA, Veves A, Masson EA, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy. J Neurol Neuosurg Psych, 1992, 55, 557-561.
32. Dyck PJ, Karnes JL, O'Brien P, Okazaki H, Lais A, Engelstad J. The spatial fiber loss in diabetic neuropathy suggests ischaemia. Ann Neuro, 1986, 19, 440-449.
33. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJM, Ward JD. Sural nerve oxygen tension in diabetes. Br Med J, 1986, 293, 1053-1054.
34. Reja A, Tesfaye S, Harris ND, Ward JD. Is ACE inhibition with Lisinopril helpful in diabetic neuropathy ? Diabetic Med, 1995, 12, 307-309.
35. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia, 1992, 35, 12-18.
36. Malik R, Abbott C, Williamson S, Carrington A, Schady W, Boulton A. ACE inhibition in human diabetic neuropathy : A double-blind placebo-controlled clinical trial. Journal of the Peripheral Nervous System 2 [abstract], 284, 1997.
37. Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy : relationship between capillary abnormalities and the severity of the neuropathy. Diabetologia, 1989, 32, 91-102.
38. Stevens MJ. Nitric oxide as a potential bridge between the metabolic and vascular hypotheses of diabetic neuropathy. Diabetic Med, 1995, 12, 292-295.